Education
About Us
Working with TipRanks
Follow Us
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H (HK:2196)
:2196
RESEARCH TOOLSreports
Total Valuation
Shanghai Fosun Pharmaceutical (Group) Co has a market cap or net worth of $62.64B. The enterprise value is ―.
Market Cap$62.64B
Enterprise Value―
Share Statistics
Shanghai Fosun Pharmaceutical (Group) Co has 551,940,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding551,940,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Shanghai Fosun Pharmaceutical (Group) Co’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 3.62%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)3.62%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee1.01M
Profits Per Employee86.61K
Employee Count40,557
Asset Turnover0.35
Inventory Turnover2.94
Valuation Ratios
The current PE Ratio of Shanghai Fosun Pharmaceutical (Group) Co is 12.79. Shanghai Fosun Pharmaceutical (Group) Co’s PEG ratio is 2.54.
PE Ratio12.79
PS Ratio0.00
PB Ratio0.71
Price to Fair Value0.75
Price to FCF-77.47
Price to Operating Cash Flow34.60
PEG Ratio2.54
Income Statement
In the last 12 months, Shanghai Fosun Pharmaceutical (Group) Co had revenue of 41.07B and earned 2.77B in profits. Earnings per share was 1.04.
Revenue41.07B
Gross Profit19.70B
Operating Income4.25B
Pretax Income4.17B
Net Income2.77B
EBITDA8.60B
Earnings Per Share (EPS)1.04
Cash Flow
In the last 12 months, operating cash flow was 989.69M and capital expenditures 0.00, giving a free cash flow of 257.89M billion.
Operating Cash Flow989.69M
Free Cash Flow257.89M
Free Cash Flow per Share0.47
Dividends & Yields
Shanghai Fosun Pharmaceutical (Group) Co pays an annual dividend of HK$0.3, resulting in a dividend yield of 1.97%
Dividend Per ShareHK$0.3
Dividend Yield1.97%
Payout Ratio25.28%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.06
52-Week Price Change4.92%
50-Day Moving Average14.69
200-Day Moving Average14.09
Relative Strength Index (RSI)43.61
Average Volume (3m)4.19M
Important Dates
Shanghai Fosun Pharmaceutical (Group) Co upcoming earnings date is Sep 2, 2025, TBA Not Confirmed.
Last Earnings DateApr 30, 2025
Next Earnings DateSep 2, 2025
Ex-Dividend DateJul 26, 2024
Financial Position
Shanghai Fosun Pharmaceutical (Group) Co as a current ratio of 0.92, with Debt / Equity ratio of 66.91%
Current Ratio0.92
Quick Ratio0.73
Debt to Market Cap0.82
Net Debt to EBITDA2.11
Interest Coverage Ratio2.96
Taxes
In the past 12 months, Shanghai Fosun Pharmaceutical (Group) Co has paid 656.84M in taxes.
Income Tax656.84M
Effective Tax Rate0.16
Enterprise Valuation
Shanghai Fosun Pharmaceutical (Group) Co EV to EBITDA ratio is 6.23, with an EV/FCF ratio of 802.71.
EV to Sales1.31
EV to EBITDA6.23
EV to Free Cash Flow802.71
EV to Operating Cash Flow11.98
Balance Sheet
Shanghai Fosun Pharmaceutical (Group) Co has $16.07B in cash and marketable securities with ¥32.06B in debt, giving a net cash position of $15.99B billion.
Cash & Marketable Securities$16.07B
Total Debt¥32.06B
Net Cash$15.99B
Net Cash Per Share$28.98
Tangible Book Value Per Share$11.11
Margins
Gross margin is 47.41%, with operating margin of 10.34%, and net profit margin of 6.74%.
Gross Margin47.41%
Operating Margin10.34%
Pretax Margin10.15%
Net Profit Margin6.74%
EBITDA Margin20.95%
EBIT Margin13.64%
Analyst Forecast
The average price target for Shanghai Fosun Pharmaceutical (Group) Co is $14.20, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$14.20
Price Target Upside2.49% Upside
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast-2.82%
EPS Growth Forecast11.93%